XOMA Royalty Corporation Watch

from 8-K 30 pages This Contingent Value Rights Agreement, Dated as of April 3, 2024 (This “Agreement”), Is Entered Into by and Between XOMA Corporation, a Delaware Corporation (The “Parent”), Xra 1 Corp., a Delaware Corporation and a Wholly Owned Subsidiary of Parent (The “Purchaser”), Broadridge Corporate Issuer Solutions, LLC, a Pennsylvania Limited Liability Company, as Rights Agent (As Defined Herein), and Fortis Advisors LLC, a Delaware Limited Liability Company, Solely in Its Capacity as the Initial Representative, Agent and Attorney In-Fact of the Holders (The “Representative”)

from 8-K 102 pages Agreement and Plan of Merger Dated as of February 16, 2024 Among XOMA Corporation Xra 1 Corp. and Kinnate Biopharma Inc

from 8-K 2 pages FDA Advises Public of Serious Adverse Event With Psoriasis Drug Raptiva

from 8-K 18 pages Non-Exclusive License Agreement

from 8-K 90 pages XOMA Ltd. 6.50% Convertible Snapssm Due 2012 Indenture Dated as of February 10, 2006 Wells Fargo Bank, National Association Trustee

from 8-K/A ~50 pages License Agreement

from 8-K/A >50 pages Collaboration Agreement

from 8-K/A ~50 pages Co-Dev. & Co-Comm. Agreement

from 8-K/A ~50 pages License Agreement

from 8-K/A ~50 pages License Agreement

from 8-K/A ~50 pages Plan of reorganization, merger, acquisition or similar

from 8-K ~50 pages Underwriting Agreement

from 8-K/A ~50 pages Amended & Restated Collaboration Agree.

from 8-K/A ~50 pages Development and License Agreement